Olympus Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Olympus is de winst gegroeid met een gemiddeld jaarlijks percentage van 5.9%, terwijl de Medical Equipment industrie de winst jaarlijks groeide met 6.2%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 5.4% per jaar. Het rendement op eigen vermogen van Olympus is 12.5%, en het heeft een nettomarge van 9%.

Belangrijke informatie

5.9%

Groei van de winst

7.2%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie	7.8%
Inkomstengroei	5.4%
Rendement op eigen vermogen	12.5%
Nettomarge	9.0%
Volgende winstupdate	14 Feb 2025

Recente prestatie-updates uit het verleden

Olympus' (TSE:7733) Strong Earnings Are Of Good Quality

Nov 15

Recent updates

Opbrengsten en kosten

Hoe Olympus geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

TSE:7733 Opbrengsten, kosten en inkomsten (JPY Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	973,595	87,726	454,212	0
30 Jun 24	966,046	27,884	484,963	0
31 Mar 24	936,210	26,610	437,938	0
31 Dec 23	916,092	39,468	421,218	0
30 Sep 23	901,507	56,534	409,494	0
30 Jun 23	875,586	126,381	386,253	0
31 Mar 23	881,923	137,809	386,396	0
31 Dec 22	933,645	137,623	406,537	0
30 Sep 22	925,858	126,848	435,004	0
30 Jun 22	891,410	121,912	384,322	0
31 Mar 22	868,867	115,742	371,206	0
31 Dec 21	793,727	95,274	346,976	0
30 Sep 21	774,113	98,063	363,424	0
30 Jun 21	785,411	84,467	340,954	0
31 Mar 21	730,544	65,599	325,489	0
31 Dec 20	715,924	46,443	357,925	0
30 Sep 20	724,722	41,459	331,437	0
30 Jun 20	752,176	42,855	345,949	0
31 Mar 20	797,411	51,670	366,691	0
31 Dec 19	807,887	60,758	381,469	0
30 Sep 19	801,202	49,704	391,969	0
30 Jun 19	795,193	33,469	403,707	0
31 Mar 19	793,862	8,147	407,644	0
31 Dec 18	795,479	15,554	409,525	0
30 Sep 18	798,915	21,732	406,066	0
30 Jun 18	795,205	30,324	402,708	0
31 Mar 18	786,497	57,064	397,223	0
31 Dec 17	786,608	85,083	346,194	39,784
30 Sep 17	767,508	85,830	340,123	39,784
30 Jun 17	751,458	79,716	333,321	39,784
31 Mar 17	748,050	78,191	334,993	39,784
31 Dec 16	745,543	60,888	327,510	41,753
30 Sep 16	758,777	48,983	334,317	41,753
30 Jun 16	785,444	54,390	345,226	41,753
31 Mar 16	804,578	62,594	348,603	41,753
31 Dec 15	807,197	2,188	354,990	35,697
30 Sep 15	805,432	4,742	348,954	35,697
30 Jun 15	785,230	-144	336,477	35,697
31 Mar 15	764,671	-8,737	323,227	35,697
31 Dec 14	749,627	39,710	323,321	29,174
30 Sep 14	734,469	43,896	312,987	29,174
30 Jun 14	721,070	23,599	307,776	29,174
31 Mar 14	713,286	13,627	302,378	29,174
31 Dec 13	696,297	6,239	299,107	28,410

Kwaliteitswinsten: 7733 heeft een grote eenmalige verlies van ¥70.3B wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 30th September, 2024.

Groeiende winstmarge: De huidige netto winstmarges (9%) 7733 } zijn hoger dan vorig jaar (6.3%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van 7733 is de afgelopen 5 jaar met 5.9% per jaar gegroeid.

Versnelling van de groei: De winstgroei van 7733 over het afgelopen jaar ( 55.2% ) overtreft het 5-jarig gemiddelde ( 5.9% per jaar).

Winst versus industrie: De winstgroei 7733 over het afgelopen jaar ( 55.2% ) overtrof de Medical Equipment -sector 5.6%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 12.5% ) van 7733 wordt als laag beschouwd.

Olympus Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Olympus' (TSE:7733) Strong Earnings Are Of Good Quality

Second quarter 2025 earnings: EPS misses analyst expectations

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Olympus Corporation to Report Q1, 2025 Results on Aug 07, 2024

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Olympus Corporation to Report Q3, 2024 Results on Feb 14, 2024

Recent updates

Olympus' (TSE:7733) Strong Earnings Are Of Good Quality

Dividend of JP¥20.00 announced

Second quarter 2025 earnings: EPS misses analyst expectations

Olympus Corporation's (TSE:7733) Share Price Could Signal Some Risk

Olympus Corporation Announces Resignation of Stefan Kaufmann as Chief Executive Officer, Effective October 28, 2024

Olympus (TSE:7733) Hasn't Managed To Accelerate Its Returns

A Look At The Intrinsic Value Of Olympus Corporation (TSE:7733)

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Olympus Corporation Announces Executive Changes, Effective October 1, 2024

High number of new directors

Does Olympus (TSE:7733) Have A Healthy Balance Sheet?

Now 22% overvalued after recent price rise

Estimating The Fair Value Of Olympus Corporation (TSE:7733)

High number of new directors

Olympus Corporation, Annual General Meeting, Jun 26, 2024

Olympus Corporation (TSE:7733) announces an Equity Buyback for 60,000,000 shares, representing 5.15% for ¥100,000 million.

Slowing Rates Of Return At Olympus (TSE:7733) Leave Little Room For Excitement

Olympus Corporation to Report Q1, 2025 Results on Aug 07, 2024

Upcoming dividend of JP¥18.00 per share

Olympus Corporation's (TSE:7733) Share Price Matching Investor Opinion

Dividend of JP¥18.00 announced

Olympus Corporation Revises Consolidated Revenue Guidance for the Fiscal Year Ending March 31, 2024

New minor risk - Earnings quality

Olympus Corporation Announces Executive Changes

Olympus Corporation (TSE:7733) completed the acquisition of Taewoong Medical Co. Ltd. from Kyong-min Shin and others.

Now 21% overvalued after recent price rise

Olympus Corporation Announces Study Results Show the S Sustained Clinical Benefits of Spiration Valve System At 24 Months

Olympus Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Olympus Corporation (TSE:7733) announces an Equity Buyback for 53,000,000 shares, representing 4.34% for ¥80,000 million.

Olympus Corporation Announces Market Launch of EVIS X1 Endoscopy System

Olympus Corporation Announces the Launch of the Vathin E-SteriScope

Investor sentiment deteriorates as stock falls 16%

New minor risk - Share price stability

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Olympus Corporation Announces Publication of Study Data Demonstrating That the Minimally Invasive Itind™? Treatment Provides Long-Lasting Relief of More Than Four Years

Olympus Corporation to Report Q3, 2024 Results on Feb 14, 2024

Full year 2023 earnings: EPS misses analyst expectations

Olympus Corporation Reiterates Consolidated Financial Guidance for the Fiscal Year Ending March 2024

Olympus Names Wenlei Yang the Newly Established Chief Diversity, Equity and Inclusion Officer

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 38%

Olympus Corporation, Annual General Meeting, Jun 27, 2023

Now 21% undervalued after recent price drop

Olympus Corporation Set to Demonstrate Newest Endoscopy System At DDW

Now 21% undervalued

Consensus EPS estimates increase by 79%

Consensus EPS estimates fall by 61%

Upcoming dividend of JP¥16.00 per share at 0.7% yield

Third quarter 2023 earnings released: EPS: JP¥28.43 (vs JP¥19.66 in 3Q 2022)

Olympus Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Consensus forecasts updated

Consensus forecasts updated

Second quarter 2023 earnings released

Second quarter 2023 earnings released

Olympus Corporation (TSE:7733) announces an Equity Buyback for 21,000,000 shares, representing 1.65% for ¥50,000 million.

Olympus Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Olympus Launches VISERA ELITE III Surgical Visualization Platform

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Bain Capital Private Equity, LP entered into a definitive agreement to acquire Scientific Solutions Business of Olympus Corporation from Olympus Corporation (TSE:7733) for approximately JPY 427.67 billion.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Olympus Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

High number of new directors

Olympus Announces the Availability of New Monitor Option, the OEV321UH Video Display Monitor

Full year 2022 earnings: Revenues in line with analyst expectations

Olympus Corporation Announces Study Results Show Long-Term Efficacy of Itind Procedure

Investor sentiment improved over the past week

Olympus Corporation to Report Q3, 2023 Results on Feb 10, 2023